Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation.

Freund P, Porpaczy EA, Le T, Gruber M, Pausz C, Staber P, Jäger U, Vanura K.

PLoS One. 2016 Jun 1;11(6):e0156693. doi: 10.1371/journal.pone.0156693. eCollection 2016.

2.

Anticancer mechanisms of cannabinoids.

Velasco G, Sánchez C, Guzmán M.

Curr Oncol. 2016 Mar;23(2):S23-32. doi: 10.3747/co.23.3080. Epub 2016 Mar 16. Review.

3.

Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress.

Farooqi AA, Li KT, Fayyaz S, Chang YT, Ismail M, Liaw CC, Yuan SS, Tang JY, Chang HW.

Tumour Biol. 2015 Aug;36(8):5743-52. doi: 10.1007/s13277-015-3797-0. Epub 2015 Jul 19. Review.

4.

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

McAllister SD, Soroceanu L, Desprez PY.

J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28. Review.

5.

Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.

Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE 3rd, Ganju RK.

Mol Oncol. 2015 Apr;9(4):906-19. doi: 10.1016/j.molonc.2014.12.010. Epub 2015 Jan 19.

6.

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

McPartland JM, Duncan M, Di Marzo V, Pertwee RG.

Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Review.

7.

Cannabinoids as therapeutic agents in cancer: current status and future implications.

Chakravarti B, Ravi J, Ganju RK.

Oncotarget. 2014 Aug 15;5(15):5852-72. Review.

8.

Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.

Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, Elwakeel E, Dayal S, Martinez-Martinez E, Amere M, Gujjar R, Mahadevan A, Desprez PY, McAllister SD.

Br J Pharmacol. 2014 Oct;171(19):4464-77. doi: 10.1111/bph.12803. Epub 2014 Sep 5.

9.

Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress.

Massi P, Valenti M, Solinas M, Parolaro D.

Cancers (Basel). 2010 May 26;2(2):1013-26. doi: 10.3390/cancers2021013.

10.

Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect.

Solinas M, Massi P, Cinquina V, Valenti M, Bolognini D, Gariboldi M, Monti E, Rubino T, Parolaro D.

PLoS One. 2013 Oct 21;8(10):e76918. doi: 10.1371/journal.pone.0076918. eCollection 2013.

11.

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA.

Br J Pharmacol. 2014 Feb;171(3):636-45. doi: 10.1111/bph.12439.

12.

Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.

Hernán Pérez de la Ossa D, Lorente M, Gil-Alegre ME, Torres S, García-Taboada E, Aberturas Mdel R, Molpeceres J, Velasco G, Torres-Suárez AI.

PLoS One. 2013;8(1):e54795. doi: 10.1371/journal.pone.0054795. Epub 2013 Jan 22.

13.

Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium.

Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X, Groopman JE.

Genes Cancer. 2012 Jul;3(7-8):512-20. doi: 10.1177/1947601912466556.

14.

Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, Khan S, Arauz R, Yount GL, Moore DH, Desprez PY, McAllister SD.

Cancer Res. 2013 Mar 1;73(5):1559-69. doi: 10.1158/0008-5472.CAN-12-1943. Epub 2012 Dec 13.

15.

Cannabidiol inhibits angiogenesis by multiple mechanisms.

Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D.

Br J Pharmacol. 2012 Nov;167(6):1218-31. doi: 10.1111/j.1476-5381.2012.02050.x.

16.

Cannabidiol as potential anticancer drug.

Massi P, Solinas M, Cinquina V, Parolaro D.

Br J Clin Pharmacol. 2013 Feb;75(2):303-12. doi: 10.1111/j.1365-2125.2012.04298.x. Review.

17.

Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.

Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA.

J Biol Chem. 2012 Jan 2;287(1):91-104. doi: 10.1074/jbc.M111.296020. Epub 2011 Oct 25.

18.

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V.

Br J Pharmacol. 2011 Aug;163(7):1479-94. doi: 10.1111/j.1476-5381.2010.01166.x.

Items per page

Supplemental Content

Write to the Help Desk